← All organizations
Highest phase reached
Phase 4
Timeline
1990s
- Jan 1, 1994
Laboratoire français de Fractionnement et de Biotechnologies— Founded
2020s
- Apr 1, 2020
coagulation factor viia (recombinant)— NDA Secondary Org
Drugs by trial phase (12 distinct, 17 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Afibrinogenemia
- Amyotrophic Lateral Sclerosis
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Motor Neuron Disease
- Polyneuropathies
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Postpartum Hemorrhage
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Shock
- Shock, Septic
- Syndrome
Marketed drugs (1)
Recent trials (17)
- NCT04350580CollaboratorPhase 3Apr 30, 2020
- NCT03370627CollaboratorN/ADec 20, 2017
- NCT02548143CollaboratorPhase 3Aug 1, 2016
- NCT02488525CollaboratorPhase 3Jan 1, 2016
- NCT02448680CollaboratorPhase 3Dec 1, 2015
- NCT02317562Lead sponsorPhase 3Nov 1, 2015
- NCT02293460Lead sponsorPhase 3May 1, 2015
- NCT02020369CollaboratorPhase 3Apr 1, 2014
- NCT02155725Lead sponsorPhase 4Apr 1, 2014
- NCT02287896Lead sponsorPhase 2/Phase 3Apr 1, 2014
- NCT02094430Lead sponsorPhase 2/Phase 3Jan 1, 2014
- NCT01951924Lead sponsorPhase 3Dec 1, 2013
- NCT01701947Lead sponsorN/AOct 3, 2012
- NCT00952575Lead sponsorPhase 2Aug 1, 2009
- NCT01098188Lead sponsorPhase 1Nov 1, 2008
Details
- Founded
- Les Ulis, FR Jan 1, 1994
- Last known activity
- Apr 30, 2020